Allograft rejection remains a major problem in clinical transplantation. In the first year post transplantation, nearly 20% of first cadaver renal allografts and 35% of retransplant grafts are rejected irreversibly despite the use of cyclosporine. Moreover, approximately 50% of renal allograft recipients suffer an acute rejection episode in the early post transplantation period which threatens the long term function of the graft and mandates additional immunosuppressive therapy. This proposal will investigate strategies for achieving long term graft acceptance in an established subhuman primate model of renal transplantation. Much of the proposal will examine the utility of highly specific immunosuppressive agents directed against the interleukin 2 receptor. lt has been shown that anti-TAC, a monoclonal antibody with specificity for the human IL-2 receptor, will prolong the survival of renal allografts. Having thus demonstrated the value of the IL-2 receptor as a target for immunosuppressive therapy, additional agents directed against this target, including monoclonal antibodies, antibody-toxin conjugates, and lymphokine- toxin conjugates, will be examined in an effort to improve and extend these results.
The specific aims of this portion of the proposal are: 1) to investigate the efficacy of additional monoclonal antibodies directed against the interleukin-2 receptor in prolonging renal allografts; 2) to develop monoclonal antibodies with specificity for the high affinity IL-2 receptor; 3) to improve the efficacy of monoclonal antibody therapy by the use of antibody- toxin conjugates; 4) to determine the effects of an interleukin-2 diphtheria toxin conjugate on the immune responsiveness of the cynomolgus monkey; and 5) to assess methods for circumventing the host immune response to administered monoclonal antibodies.
Other specific aims will study the effects of Mab's defining subsets of T lymphocytes which induce help or suppression and of antibodies directed to varied epitopes of CD4. The experiments will be conducted in cynomolgus monkey recipients of renal allografts treated with one or a combination of the agents. In addition to graft survival, the impact of these agents on immune function and the host immune response to the therapy will be investigated. It is anticipated that these experiments will lead to the identification of agents which may be of value in clinical transplantation.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1996) Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 156:1714-21
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1995) A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 270:14107-14
Martin-Reay, D G; Kamentsky, L A; Weinberg, D S et al. (1994) Evaluation of a new slide-based laser scanning cytometer for DNA analysis of tumors. Comparison with flow cytometry and image analysis. Am J Clin Pathol 102:432-8
Araten, D J; Lawton, T; Ferrara, J et al. (1993) In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation 55:76-82
Sayegh, M H; Khoury, S J; Hancock, W W et al. (1993) Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc 25:357-8
Weinberg, D S; Weidner, N (1993) Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117:1132-7
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 82:2224-34
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation 56:1188-96
Hancock, W W; Sayegh, M H; Kwok, C A et al. (1993) Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 55:1112-8
Dawson, A E; Cibas, E S; Bacus, J W et al. (1993) Chromatin texture measurement by Markovian analysis. Use of nuclear models to define and select texture features. Anal Quant Cytol Histol 15:227-35

Showing the most recent 10 out of 30 publications